Bay Area's Ardelyx Nabs $160M Deal With Kyowa Hakko Kirin
Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million. Source: BioSpace
Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million. Source: BioSpace
Clovis Oncology has solidified its physical footprint in the Bay Area with a 32,000 square foot space it secured for 10 years through property developer TMG Partners. Source: BioSpace
The deal aims to accelerate local development of innovative medicines for patients in China and builds on AstraZeneca’s strong presence in the country. Source: BioSpace
While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population. Source: BioSpace
News of the layoffs comes hard on the heels of the company's credit rating having been cut to junk status by Fitch Rating. Source: BioSpace
Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.…
Biogen will receive an exclusive, worldwide license to commercialize ALKS 8700 and will pay Alkermes a mid-teens royalty on worldwide net sales of ALKS 8700. Source: BioSpace
The financing will be used to push its Phase III clinical program of MDR-101 in living donor HLA-matched kidney transplant patients. Source: BioSpace
Qiagen's investment will be an expansion of its current operations in that northern England city. Source: BioSpace
The move is in part related to Brexit, the UK's exit from the European Union. Source: BioSpace